Acknowledgements

Conference Secretariat and Local Organization:

• (based in Bellinzona, Switzerland)
• C. Brentan, O. Lugli, C. Saporiti.

The conference organizers wish to thank the following sponsors for their unrestricted financial support:

• Abbvie
• Acerta Pharma
• Amgen (Europe) GmbH
• Bayer HealthCare Pharmaceuticals, Inc.
• Bristol-Myers Squibb
• Celgene Corporation
• CTI Life Sciences Ltd.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Gilead Sciences Europe Ltd.
• Infinity Pharmaceuticals, Inc.
• Institut Biochimique SA – IBSA
• Janssen Pharmaceutical Companies of Johnson & Johnson
• Medicom Worldwide, Inc.
• Mentrik Biotech, LLC
• Mundipharma Oncology
• Novartis Oncology
• Pfizer Oncology
• Seattle Genetics, Inc.
• Servier
• sigma-tau Research Switzerland SA
• Spectrum Pharmaceuticals, Inc.
• Takeda Oncology
• Vifor SA

The conference organizers wish to thank the following contributors for their support:

• American Association for Cancer Research – AACR
• Arcobaleno – Comunità Tariffale Ticino e Moesano
• City of Lugano
• European School of Oncology – ESO
• European Society for Medical Oncology – ESMO
• European Society for Radiotherapy and Oncology - ESTRO
• Hotel Splendide Royal
• Institut Carnot – CALYM
• International Extranodal Lymphoma Study Group – IELSG
• International Lymphoma Radiation Oncology Group – ILROG
• Kompetenznetz Maligne Lymphome e.V. – KML
• Leukämiehilfe Rhein-Main g.e.V. – LHRM
• Lugano University Campus
• Lymphoma Coalition
• Lymphoma HUB
• Omega SA
• Repubblica e Cantone Ticino/Fondo Swisslos
• San Salvatore Foundation
• Schweizerische Patientenorganisation für Lymphombetroffene und Angehörige – ho / noho
• Swiss Cancer League
• Swiss Cancer Research Foundation
• Swiss International Air Lines
• The Leukemia Lymphoma Society
• The MDS Alliance
• Ticino Tourism

SAVE THE DATE: 14-ICML – 14th International Conference on Malignant Lymphoma

Lugano, Switzerland

June 14-17, 2017

Satellite Symposia Schedule

Conference Schedule

Tuesday, June 16, 2015

09:30–17:30 Auditorium, University Campus	Closed workshop: ‘follicular lymphoma: recent insights and future directions (moving towards biology-driven treatments?)’*
	Co-Chairs: R.D. Gascoyne, Vancouver, BC (Canada) and E. Zucca, Bellinzona (Switzerland)
	Supported by American Association for Cancer Research – AACR and European School of Oncology – ESO
	*by invitation only
15:00–18:00	workshop on radiotherapy for lymphoma: ‘controversies in the use of radiation therapy for advanced stage lymphoma’**
Cinema Corso	Co-Chairs: D. Hodgson, Toronto, ON (Canada) and T. Illidge, Manchester (UK)
	Organized by International Lymphoma Radiation Oncology Group – ILROG
	**open to all 13-ICML attendees

Wednesday, June 17, 2015

08:30–12:00		POSTER SESSION SET UP (Marquee Parco Ciani)
08:30–09:15 5 parallel sessions	Article number	‘MEET THE PROFESSOR’ SESSIONS
Room A	IV.	Masses in the mediastinum: primary mediastinal lymphoma and intermediate types
		P.M.W. Johnson, Southampton (UK)
		repeated on Thursday, June 18, in Auditorium, University Campus
Room B	VII.	Are lymphomas driven by epigenetic lesions? A.M. Melnick, New York, NY (USA)
		repeated at 09:30 in Cinema Corso
Cinema Corso	X.	Challenges and future directions in peripheral t-cell lymphoma
		K.J. Savage, Vancouver, British Columbia (Canada)
		repeated at 09:30 in Room B
Auditorium, University Campus	III.	Current concepts in primary central nervous lymphoma
		G. Illerhaus, Stuttgart (Germany)
		repeated on Thursday, June 18, in Cinema Corso
Aula Magna, University Campus	IX.	Is it only about myc? how to approach the diagnosis of diffuse large b-cell lymphomas
		L. Quintanilla-Martinez, Tuebingen (Germany)
		repeated on Friday, June 19, in Cinema Corso
09:30–10:15 5 parallel sessions
Room A	VIII.	Treatment of cll, where are we heading?
		S.M. O'Brien, Irvine, CA (USA)
		repeated on Friday, June 19, in Auditorium, University Campus
Room B	X.	Challenges and future directions in peripheral t-cell lymphoma
		K.J. Savage, Vancouver, BC (Canada)
Cinema Corso	VII.	Are lymphomas driven by epigenetic lesions?
		A.M. Melnick, New York, NY (USA)
Auditorium, University Campus	XII.	Therapeutic exploitation of autologous t-cell activation in b-cell lymphoma
		A. Younes, New York, NY (USA)
		repeated on Thursday, June 18, in Room A
Aula Magna, University Campus	VI.	FDG-pet as a biomarker in lymphoma: from qualitative to quantitative analysis
		M. Meignan, Creteil (France)
		repeated on Friday, June 19, in Aula Magna, University Campus
10:15–10:35		COFFEE BREAK (Marquee Parco Ciani)
10:35–12:00 2 parallel sessions		EDUCATIONAL SYMPOSIA
Room A – Marquee (overflow area)		HISTOLOGICAL TRANSFORMATION IN LYMPHOMA: CLINICAL, PATHOLOGICAL AND MOLECULAR FEATURES
		Chair: J.G. Gribben, London (UK)
		LECTURES:
	XIII.	Molecular pathogenesis of transformed lymphomas
		D. Rossi, Novara (Italy)
	XIV.	The pathology of transformation of lymphoma
		R.D. Gascoyne, Vancouver, BC (Canada)
	XV.	Clinical aspects of transformed lymphoma
		J.G. Gribben, London (UK)
Room B		Hodgkin lymphoma – challenges and opportunities
		Chair: R.H. Advani, Stanford, CA (USA)
		LECTURES:
	XVI.	Early stage hodgkin lymphoma
		J.A. Radford, Manchester (UK)
	XVII.	Treatment of advanced-stage hodgkin lymphoma
		A. Engert, Cologne (Germany)
	XVIII.	Management of nodular lymphocyte predominant hodgkin lymphoma
		R.H. Advani, Stanford, CA (USA)
12:00–18:30 Marquee	Abstract number	POSTER SESSION
		(printing of the posters sponsored by Takeda Oncology)
	148–170	Pathology and biology
	171–181	Hodgkin lymphoma
	182–186	CLL
	187–201	Indolent lymphoma
	202–209	Mantle cell lymphoma
	210–224	Aggressive b-cell lymphoma
	225–230	Extranodal lymphoma
	231–250	T-Cell lymphoma
	251–259	Imaging
	260–279	Pre-clinical studies
	280–287	Early clinical trials
	OT07–OT15	Ongoing trials
12:00–13:00 Marquee		LUNCH TIME AND POSTER VIEWING
13:00–14:00 Room A, B and Marquee (overflow area)		OPENING OF THE CONFERENCE
		Welcome and introductory remarks
		F. Cavalli, Bellinzona (Switzerland)
		Henry kaplan memorial lecture and san salvatore foundation award
		Introduction to San Salvatore Foundation: L. Butti, Lugano (Switzerland)
		Laudatio: R. Stahel, Zurich (Switzerland)
	001	Therapy of lymphoma inspired by functional and structural genomics
		L.M. Staudt, Bethesda, MD (USA)
14:00–15:15 Room A, B and Marquee (overflow area)		PLENARY SESSION
		Co-Chairs: G.P. Canellos, Boston, MA (USA) and J.W. Friedberg, Rochester, NY (USA)
14:00	008	Response-adapted therapy based on interim fdg-pet scans in advanced hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international rathl study (CRUK/07/033)
		P.M.W. Johnson, Southampton (UK)
14:15		Discussant: A. Engert, Cologne (Germany)
14:25	009	Addition of thiotepa and rituximab to antimetabolites significantly improves outcome in primary cns lymphoma: first randomization of the IELSG32 trial
		A.J. Ferreri, Milan (Italy)
14:40		Discussant: T.T. Batchelor, Boston, MA (USA)
14:50	010	Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical hodgkin lymphoma: updated results of a Phase 1 study (CA209-039)
		J. Timmerman, Los Angeles, CA (USA)
15:05		Discussant: A. Younes, New York, NY (USA)
15:15–15:40 Marquee		COFFEE BREAK
15:40–16:40 Room A, B and Marquee (overflow area)		AACR-ICML JOINT SESSION: SPECIAL LECTURES
		Co-Chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)
15:40	004	Update on the revision of the who lymphoma classification
		S.H. Swerdlow, Pittsburgh, PA (USA)
16:10	005	What's new in multiple myeloma?
		S.V. Rajkumar, Rochester, MN (USA)
16:40–17:15		BREAK
17:15–18:15 6 parallel sessions		‘FOCUS ON…’ SESSIONS
Room A		IMIDs in lymphoma
		Chair: N. Fowler, Houston, TX (USA)
17:15	011	Independent review of ct responses in the trial SAKK35/10 comparing rituximab with or without lenalidomide in untreated FL patients in need of therapy
		E. Zucca, Bellinzona (Switzerland)
17:25	012	Rituximab+Lenalidomide in malt lymphoma: final results
		M. Raderer, Vienna (Austria)
17:35	013	Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): a Phase 1 study
		J.S. Abramson, Boston, MA (USA)
17:45	014	Rituximab, lenalidomide, bendamustine second line therapy in mantle cell lymphoma: A Phase II study of the fondazione italiana linfomi (FIL)
		F. Zaja, Udine (Italy)
17:55	015	Rituximab, bendamustine and lenalidomide in patients with relapsed/refractory aggressive b-cell lymphoma not eligible for salvage chemotherapy. Phase II trial – SAKK 38/08
		F. Hitz, St. Gallen (Switzerland)
18:05	016	A Phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma
		N. Mehta-Shah, New York, NY (USA)
Room B		Genomic alterations
		Chair: G. Gaidano, Novara (Italy)
17:15	017	Sequence-based panomics analyses by the ICGC MMML-SEQ deciphers multi-layer pathway deregulation in germinal center derived B-cell lymphomas
		R. Siebert, Kiel (Germany)
17:25	018	Structural variants in germinal-center derived B-cell lymphomas: analyses in the framework of the ICGC MMML-SEQ porject
		C. Lopez, Kiel (Germany)
17:35	019	Comprehensive genomic profiling of diffuse large B-cell lymphoma in the clinical setting
		J. He, Cambridge, MA (USA)
17:45	020	Targeted genomic sequencing prospectively identifies clinically relevant genetic alterations across lymphoma subtypes
		C.L. Batlevi, New York, NY (USA)
17:55	021	Posttransplant diffuse large B-cell lymphoma and burkitt lymphoma: new genetic findings
		I. Wlodarska, Leuven (Belgium)
18:05	022	Microrna-150 influences microenvironmental interactions and prognosis of follicular lymphoma
		M. Mraz, Brno (Czech Republic)
Room C		Clinicopathological correlations
		Chair: M.A. Piris, Santander (Spain)
17:15	023	Frequencies of lymphoma entities and impact of diagnostic review: a french experience on 35.753 lymphomas over 2010–2013
		C. Laurent, Toulouse (France)
17:25	024	Rituximab treatment in follicular lymphoma circumvents the prognostic value of intra-tumoral t-cells: automated image analysis of the lysa prima trial
		L. Xerri, Marseille (France)
17:35	025	Cell of origin (COO) assignment in transformed follicular lymphoma
		R. Kridel, Vancouver, British Columbia (Canada)
17:45	026	NOTCH1/2 mutations are recurrently found in cyclin D1-negative SOX11-positive mantle cell lymphoma
		I. Salaverria, Barcelona (Spain)
17:55	027	Clinicopathological study of HHV8-negative body cavity-based lymphoma (BCBL)
		D. Kaji, Tokyo (Japan)
18:05	028	Grey zone lymphoma between classical hodgkin lymphoma and diffuse large B-cell lymphoma: a lysa retrospective analysis
		C. Sarkozy, Pierre Bénite (France)
Cinema Corso		Transplantation
		Chair: S. Montoto, London (UK)
17:15	029	Beam plus rituximab or radioimmunotherapy versus beam for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma: a retrospective study of the LWP-EBMT
		L. Bento, Paris (France)
17:25	030	Outcome of reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after a previous autologous stem cell transplant
		S. Robinson, Bristol (UK)
17:35	031	A UK lymphoma clinical study group Phase II evaluation of high-dose chemotherapy and autologous stem cell transplantation in intestinal and other aggressive t-cell lymphomas
		M.M. Lannon, Newcastle upon Tyne (UK)
17:45	032	Allogeneic transplantation for T-cell lymphomas: no difference in outcome between patients allografted up-front and in first chemosensitive relapse
		A. Dodero, Milan (Italy)
17:55	033	Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma – results of the interim analysis of the AATT trial
		N. Schmitz, Hamburg (Germany)
18:05	034	Post transplant cyclophosphamide reduces non relapse mortality of haplo-identical transplants yielding similar outcomes as with matched sibling donors
		S. Dietrich, Heidelberg (Germany)
Auditorium, University Campus		Novel agents
		Chair: G. Salles, Pierre Bénite (France)
17:15	035	Lipid addiction of DLBCL: involvement of PI3K signaling and potential therapeutic strategies via fatty acid synthase small molecule inhibitors
		A. Evens, Boston, MA (USA)
17:25	036	EZH2 and MYD88 mutations appear associated with antitumor activity of three new bet bromodomain inhibitors (BAY-5627, BAY-7575 and BAY-8097) in preclinical lymphoma models
		E. Bernasconi, Bellinzona (Switzerland)
17:35	037	Venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/?refractory (r/r) multiple myeloma (MM): Phase 1 results
		S. Heitner Enschede, Chicago, IL (USA)
17:45	038	TGR-1202, a novel once daily PI3Kδ inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity in patients with cll and B-cell lymphoma
		H.A. Burris III, Nashville, TN (USA)
17:55	039	Ongoing, first-in-human, Phase 1 dose-escalation study of investigational SYK inhibitor TAK-659 in patients with advanced solid tumors or lymphoma
		A.M. Petrich, Chicago, IL (USA)
18:05	040	ARGX-110, a novel monoclonal antibody targeting CD70, is associated with biological activity in patients with relapsed/?refractory T-cell lymphomas
		M. Maerevoet, Villejuif (France)
Aula Magna, University Campus		Short- and long-term toxicity of lymphoma therapies
		Chair: M.F. Fey, Bern (Switzerland)
17:15	041	Pulmonary function and grade 3/4 clinical events in pet negative patients taking part in the international rathl trial (CRUK/07/033): a comparison of 12 vs 4 doses of bleomycin
		C. Hague, Manchester (UK)
17:25	042	SYK & PI3K δ pathway inhibition resulted in increased rates of pneumonitis: implications for developing future small molecule combinations
		P.M. Barr, Rochester, NY (USA)
17:35	043	Cardiovascular disease after therapy for hodgkin lymphoma: a detailed analysis of 9 collaborative eortc-LYSA trials
		M. Maraldo, Copenhagen (Denmark)
17:45	044	A radiation dose-response relationship for risk of coronary heart disease in survivors of hodgkin lymphoma: a case-control study
		B.M. Aleman, Amsterdam (The Netherlands)
17:55	045	Anticoagulant/antiplatelet therapy concomitant with idelalisib in chronic lymphocytic leukemia and indolent NHL: use and outcomes
		P. Ghia, Milan (Italy)
18:05	046	Patterns of cognitive difficulties after treatment for lymphoma
		O.C. Lindner, Manchester (UK)

Thursday, June 18, 2015

08:30–18:30 Marquee		POSTER SESSION
08:00–08:45 5 parallel sessions	Article number	‘MEET THE PROFESSOR’ SESSIONS
Room A	XII.	Therapeutic exploitation of autologous T-cell activation in B-cell lymphoma
		A. Younes, New York, NY (USA)
Room B	XI.	Management of pediatric and adult non hodgkin lymphoma: what lessons can each teach the other?
		B. Burkhardt, Muenster (Germany) and J.F. Seymour, Melbourne (Australia)
Cinema Corso	III.	Current concepts in primary central nervous lymphoma
		G. Illerhaus, Stuttgart (Germany)
Auditorium, University Campus	IV.	Masses in the mediastinum: primary mediastinal lymphoma and intermediate types
		P.M.W. Johnson, Southampton (UK)
Aula Magna, University Campus	V.	Smoldering multiple myeloma
		M.V. Mateos, Salamanca (Spain)
09:00–10:35 Room A and Marquee (overflow area)	Abstract number	SESSION 1 – LYMPHOMA BIOLOGY AND GENOMICS I
		Co-Chairs: R. Dalla-Favera, New York, NY (USA) and R.D. Gascoyne, Vancouver, British Columbia (Canada)
09:00	047	Introduction: Germinal centers and lymphomagenesis
		R. Dalla-Favera, New York, NY (USA)
09:20	048	Whole exome sequencing of refractory aggressive B-cell lymphomas identified recurrent mutations of the exportin 1 gene (XPO1) in primary mediastinal B-cell lymphoma subtype. a LYSA study
		F. Jardin, Rouen (France)
09:35	049	Recurrent somatic mutations in diffuse large b-cell lymphoma assessed by high-throughput targeted sequencing highlight molecular subtypes' genetic divergence: a LYSA study
		S. Dubois, Rouen (France)
09:50	050	A modified autoantigen is the first molecularly defined risk factor and a dominant antigenic target / stimulus of the b-cell receptor from ABC-type DLBCL
		M. Pfreundschuh, Homburg (Germany)
10:05	051	The role of tonic bcr signaling in a mouse model of MYC-driven lymphoma
		S. Casola, Milan (Italy)
10:20	052	Recurrent mtorc1-activating RRAGC mutations are a feature of follicular lymphoma
		J. Okosun, London (UK)
09:00–10:30 5 parallel sessions		‘CASE DISCUSSION’ SESSIONS
		Italian Lymphoma Foundation – FIL vs Cornell University and Memorial Sloan-Kettering Cancer Center in New York, NY (USA)
Room B		Indolent lymphoma
		Chair: A. Davies, Southampton (UK)
		Discussants: L. Arcaini, Pavia (Italy) and J.P. Leonard, New York, NY (USA)
Room C		Pediatric and adolescent lymphoma
		Chair: W. Wössmann, Giessen (Germany)
		Discussants: M. Pillon, Padua (Italy) and C.E. Allen, Houston, TX (USA)
Cinema Corso		CLL
		Chair: J.G. Gribben, London (UK)
		Discussants: R. Foà, Rome (Italy) and A.D. Zelenetz, New York, NY (USA)
Auditorium, University Campus		T-cell lymphoma
		Chair: F. d'Amore, Aarhus (Denmark)
		Discussants: P. Corradini, Milan (Italy) and S. Horwitz, New York, NY (USA)
Aula Magna, University Campus		Hodgkin lymphoma
		Chair: J.A. Radford, Manchester (UK)
		Discussants: P.L. Zinzani, Bologna (Italy) and A. Younes, New York, NY (USA)
10:35–11:00 Marquee		COFFEE BREAK
11:00–12:00 Room A, B and Marquee (overflow area)		SESSION 2 – ADVANCES IN CLL
		Co-Chairs: M. Hallek, Cologne (Germany) and A.D. Zelenetz, New York, NY (USA)
11:00	053	In-vivo studies of kinetics in chronic lymphocytic leukaemia provide definitive evidence of LYMPH-node re-entry and suggest that there is a non-proliferative sub-clone
		K. Cuthill, London (UK)
11:15	054	The international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI) – an international meta-analysis
		J. Bahlo, Cologne (Germany)
11:30	055	Efficacy of ibrutinib vs ofatumumab by cytogenetic and clinical subgroups in a Phase 3 trial in patients with previously treated CLL/SLL
		P. Thornton, Dublin (Ireland)
11:45	056	BFR (bendamustine, fludarabine, rituximab) allogeneic conditioning improves survival in CLL
		I.F. Khouri, Houston, TX (USA)
12:00–13:00 Marquee		LUNCH TIME AND POSTER VIEWING
		from 12:30 to 13:00 authors in front of their posters for discussion with attendees
13:00–13:45 Room A, B and Marquee (overflow area)		HENRY RAPPAPORT MEMORIAL LECTURE
		Chair: P. Gaulard, Créteil (France)
	002	MANTLE CELL LYMPHOMA, AN UNFOLDING STORY FROM THE MICROSCOPE TO THE GENOME
		E. Campo, Barcelona (Spain)
13:00–17:00 Cinema Corso		WORKSHOP FOR RADIATION ONCOLOGISTS
		Co-Chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)
		Organized by International Lymphoma Radiation Oncology Group - ILROG
		Part 1: Technical challenges in radiation therapy of lymphomas
		B. Dabaja, Houston, TX (USA)
		Part 2: Panel discussion: COMPETENCIES FOR RADIATION ONCOLOGISTS WITH SPECIAL EXPERTISE IN LYMPHOMAS
13:45 – 15:15 Room A, B and Marquee (overflow area)		SESSION 3 – MANTLE CELL LYMPHOMA
		Co-Chairs: M. Dreyling, Munich (Germany) and P. Martin, New York, NY (USA)
13:45	057	PI3K INACTIVATION AND REDOX STRESS MEDIATES THERAPEUTIC TARGETING OF CDK4 IN MCL
		S. Chen-Kiang, New York NY (USA)
14:00	058	PROGNOSTIC VALUE OF PROLIFERATION, CYTOLOGY, AND GROWTH PATTERN IN MANTLE CELL LYMPHOMA: RESULTS FROM RANDOMIZED TRIALS OF THE EUROPEAN MCL NETWORK
		E. Hoster, Munich (Germany)
14:15	059	RITUXIMAB, BENDAMUSTINE AND CYTARABINE (RBAC500) AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: A PHASE 2 STUDY FROM THE FONDAZIONE ITALIANA LINFOMI
		C. Visco, Vicenza (Italy)
14:30	060	LENALIDOMIDE-RITUXIMAB-BENDAMUSTINE IN FIRST LINE FOR PATIENTS > 65 WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE NORDIC LYMPHOMA GROUP MCL4 (LENA-BERIT) PHASE I/II TRIAL
		A. Albertsson-Lindblad, Lund (Sweden)
14:45	061	RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS ASCT IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSA STUDY
		S. Le Gouill, Nantes (France)
15:00	062	RESULTS OF A RANDOMIZED PHASE II TRIAL OF R-HCVAD VS. R-BENDAMUSTINE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTS FOR PATIENTS WITH MANTLE CELL LYMPHOMA: US INTERGROUP S1106
		R. Chen, Duarte, CA (USA)
14:45–16:55		SESSION 4 - PEDIATRIC LYMPHOMA
Room C		Chair: W. Wössmann, Giessen (Germany)
14:45	063	Nodular lymphocyte predominant hodgkin lymphoma in children and adolescents: therapeutic approaches and grey zone to mature B-NHL
		C. Mauz-Körholz, Halle (Germany)
15:05	064	New targets for the treatment of mature B-NHL
		F. Jardin, Rouen (France)
15:25–15:40		COFFEE BREAK – Inside Room C for session 4 attendees
15:40	065	Results of the randomized trial EURO-LB02 on lymphoblastic lymphoma in children and adolescents – a report of the European intergroup for childhood non-hodgkin lymphoma
		B. Burkhardt, Muenster (Germany)
15:55	066	Relapses in children/adolescents with mature B-cell lymphoma/leukemia treated in the rituximab era – a study of the Société Française des Cancers de L'enfant
		V. Minard-Colin, Villejuif (France)
16:10	067	Treatment and characterization of patients with Burkitt Lymphoma (BL): Results from a single institution in Northern Uganda
		V. Calbi, Gulu (Uganda)
16:25	068	Risk-adapted approach for patients with relapsed or refractory ALCL – final report of the prospective ALCL-relapse trial of the EICNHL
		S. Ruf, Giessen (Germany)
16:40	069	Lymphoma associated with a constitutional mismatch repair deficiency syndrome: clinical description in a french cohort
		N. Lavoine, Villejuif (France)
15:15–15:35 Marquee		COFFEE BREAK
15:35–17:05Room A and Marquee (overflow area)		SESSION 5 – T-CELL LYMPHOMA
		Co-Chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)
15:35	070	T-cell project: an international, prospective, observational study of patients with aggressive peripheral NK/T-cell lymphoma. lesson from the first 1308 patients
		M. Federico, Modena (Italy)
15:50	071	The genetic landscape of hepatosplenic T-cell lymphoma reveals novel strategies for treatment and risk-stratification
		P. Gaulard, Créteil (France)
16:05	072	A PTCL, NOS subset with molecular and clinical features similar to AITL
		M. Dobay, Lausanne (Switzerland)
16:20	073	Radiation therapy for primary cutaneous anaplastic large cell lymphoma (pcALCL): an international lymphoma radiation oncology group (ILROG) multi-institutional experience
		R.T. Hoppe, Stanford, CA (USA)
16:35	074	Ten years median follow-up of the Nordic NLG-T-01 trial on choep and upfront autologous transplantation in peripheral T-cell lymphomas
		F. d'Amore, Aarhus (Denmark)
16:50	075	5-year follow-up of the smile Phase II study for newly-diagnosed Stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type
		R. Suzuki, Izumo (Japan)
15:35–16:55		SESSION 6 – INTERFERING WITH BCR-NFKB PATHWAYS
Room B		Co-Chairs: M.A. Shipp, Boston, MA (USA) and F.E. Cotter, London (UK)
15:35	076	Introduction: BCR SIGNALING AND SURVIVAL PATHWAYS IN LYMPHOMA
		M.A Shipp, Boston, MA (USA)
15:55	077	Ibrutinib is highly active and produces durable responses in previously treated waldenström's macroglobulinemia
		S. Treon, Boston, MA (USA)
16:10	078	The novel dual PI3K/MTOR inhibitor PQR309 shows preclinical activity as single agent or in combination and targets central signaling pathways in B-cell lymphomas
		C. Tarantelli, Bellinzona (Switzerland)
16:25	079	Phase 1 study of PI3Kδ inhibitor INCB040093 alone or in combination with selective JAK1 inhibitor INCB039110 in patients with relapsed/refractory B-cell malignancies
		T.J. Phillips, Ann Arbor, MI (USA)
16:40	080	A first-in-human trial of CUDC-907, an oral, first-in-class, dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma and multiple myeloma
		A. Younes, New York, NY (USA)
17:15–18:15 6 parallel sessions		‘FOCUS ON…’ SESSIONS
Room A		Imaging
		Chair: B.D. Cheson, Washington, DC (USA)
17:15	081	Use of the lugano classification criteria for PET/CT assessment of primary mediastinal B-CELL lymphoma after immunochemotherapy and irradiation in the IELSG-26 study
		L. Ceriani, Bellinzona (Switzerland)
17:25	082	PET score following 3 cycles ABVD has greater prognostic value than pre-treatment risk stratification in the rapid trial in early stage hodgkin lymphoma (HL)
		J. Radford, Manchester (UK)
17:35	083	Baseline total metabolic volume (TMTV0) predicts the outcome of patients with diffuse large B-cell lymphoma (DLBCL) enrolled in the LNH07-3B LYSA trial
		O. Casasnovas, Créteil (France)
17:45	084	Prognostic value of baseline total metabolic tumour volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)
		A. Cottereau, Rouen (France)
17:55	085	Little value of routine surveillance imaging for primary CNS lymphomas in first remission: results from a danish multicenter study
		K. Juul Mylam, Odense (Denmark)
18:05	086	Routine imaging for diffuse large B-CELL lymphoma in first remission is not associated with better survival: a danish–swedish population-based study
		T.C. El-Galaly, Aalborg (Denmark)
Room B		Targetting CD30
		Chair: P. Borchmann, Cologne (Germany)
17:15	087	Brentuximab vedotin plus AVD for non-bulky limited stage classical hodgkin lymphoma: a Phase 2 trial
		J.S. Abramson, Boston, MA (USA)
17:25	088	Preliminary efficacy and safety of brentuximab vedotin and AVD chemotherapy followed by involved-site radiotherapy in early stage, unfavorable risk hodgkin lymphoma
		A. Kumar, New York, NY (USA)
17:35	089	Sequential brentuximab vedotin and AVD for older hodgkin lymphoma patients: initial results from a Phase 2 multicenter study
		A.M. Evens, Boston, MA (USA)
17:45	090	A Phase 1 study of brentuximab vedotin (BV) and bendamustine (B) in relapsed or refractory hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL)
		J. Kuruvilla, Toronto, ON (Canada)
17:55	091	Brentuximab vedotin demonstrates antitumor activity in CD30+ DLBCL
		M.R. Smith, Boston, MA (USA)
18:05	092	Updated results of a Phase 2 trial of brentuximab vedotin combined with RCHOP in frontline treatment of pts with high-intermediate/high-risk DLBCL
		S.M. Ansell, Rochester, MN (USA)
Room C		Epidemiology and infections
		Chair: L. Arcaini, Pavia (Italy)
17:15	093	International dlbcl study finds biological heterogeneity between ethnically diverse countries but similar IPI-adjusted outcomes
		R. Carr, London (UK)
17:25	094	Involvement of moraxella catarrhalis in the pathogenesis of hodgkin lymphoma (nodular lymphocyte predominant type, IGD-positive)
		S. Hartmann, Frankfurt (Germany)
17:35	095	EPSTEIN-BARR virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival
		C. Visco, Vicenza (Italy)
17:45	096	Exposure to hepatitis B virus (HBV), family history, and B-CELL non-hodgkin lymphoma (B-NHL): a case-control study among Jews and Arabs in Israel and the West bank
		O. Paltiel, Jerusalem (Israel)
17:55	097	EBV positive dlbcl of the elderly is a heterogeneous disorder with outcome predicted by its immune microenvironment
		C. Keane, Brisbane (Australia)
18:05	098	The role of HBV-infection in chronic lymphocytic leukemia
		W. Xu, Nanjing (China)
Cinema Corso		Management of T-cell lymphoma
		Chair: F. d'Amore, Aahrus (Denmark)
17:15	099	CHOEP VS. CHOP gives better results in first-line therapy of T-cell lymphoma. A retrospective analysis from Czech lymphoma study group (CLSG) databse
		A. Janikova, Brno (Czech Republic)
17:25	100	Long-term outcome of adults with ALCL after the first relapse/progression: A LYSA study
		D. Sibon, Paris (France)
17:35	101	Prospective Phase II trial of lenalidomide in association with chop in elderly patients with angioimmunoblastic T-cell lymphoma (AITL): interim analysis of a LYSA study
		V. Safar, Lyon (France)
17:45	102	Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal NK/T-cell lymphoma
		H. Yhim, Jeonju (Korea)
17:55	103	P-GEMOX regimen followed by extensive involved-field radiotherapy for newly diagnosed Stage I/II ENKTL
		H. Hui-Qiang, Guangzhou (China)
18:05	104	HDAC inhibitor combinations exhibit synergy in pre- and clinical experiences in drug resistant T-cell lymphoma
		O.A. O'Connor, New York, NY (USA)
Auditorium, University Campus		New drug combinations
		Chair: J.P. Leonard, New York, NY (USA)
17:15	105	Ublituximab (TG-1101), a novel glycoengineered anti-CD20 MAB, in combination with ibrutinib achieves 95% orr in patients with high-risk relapsed/?refractory CLL
		J. Burke, Aurora, CO (USA)
17:25	106	The chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib is safe and highly active in relapsed B-cell malignancies
		L. Nastoupil, Houston, TX (USA)
17:35	107	A Phase 1 study of PI3Kδ inhibitor INCB040093 alone or in combination with selective JAK1 inhibitor INCB039110 in patients with relapsed/?refractory hodgkin lymphoma
		A. Forero-Torres, Birmingham, AL (USA)
17:45	108	ABT-199 triggers apoptosis, and augments ibrutinib cytotoxicity in CXCR4 wild-type and whith mutated waldenstroem macroglobulinemia cells
		J.J. Castillo, Boston, MA (USA)
17:55	109	Venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/?refractory multiple myeloma: Phase 1B results
		A.A. Chanan-Khan, Jacksonville, FL (USA)
18:05	110	Cancer energy metabolism as a therapeutic target in refractory MYC+ diffuse large B-CELL lymphoma
		C. Thieblemont, Paris (France)
Aula Magna, University Campus		Ongoing trials
		Chair: A. Davies, Southampton (UK)
17:15	OT01	The IELSG-37 study: a randomized trial assessing the role of mediastinal radiotherapy after front-line rituximab and anthracycline containing regimens in patients with primary mediastinal large B-cell lymphoma (PMLBCL)
		M. Martelli, Rome (Italy)
17:25	OT02	Rochop study: a Phase III randomized study of chop compared to romidepsin-chop in untreated peripheral T-cell lymphoma
		R. Delarue, Paris (France)
17:35	OT03	CLL2-BIG, -BAG, -BCG AND -BIO: Four Phase-II trials evaluating a sequential tailored and targeted regimen aiming for total eradication of MRD in an all-comer CLL population
		P. Cramer, Cologne (Germany)
17:45	OT04	Phase 2 study of venetoclax (GDC-0199/ABT-199) plus bendamustine and rituximab (BR) vs. BR or venetoclax plus rituximab in relapsed/refractory FL
		W. Hiddemann, Munich (Germany)
17:55	OT05	DLC-002 (ROBUST): Phase III randomized, efficacy and safety study of lenalidomide plus R-chop vs R-chop in patients with untreated ABC-type diffuse large B-cell lymphoma
		A. Chiappella, Turin (Italy)
18:05	OT06	Randomized, multicenter, open-label, Phase 3 study of ibrutinib/?obinutuzumab vs. chlorambucil/obinutuzumab for treatment-naïve CLL/SLL (PCYC-1130; ILLUMINATE)
		C. Moreno, Barcelona (Spain)

Friday, June 19, 2015

08:30–18:30 Marquee		POSTER SESSION
08:00–08:45 5 parallel sessions	Article number	MEET THE PROFESSOR SESSIONS
Room A	I.	Hodgkin lymphoma: special challenges and solutions
		J. M. Connors, Vancouver, British Columbia (Canada)
Room B	II.	Challenges in the management of PTLD
		G. Gaidano, Novara (Italy)
Cinema Corso	IX.	Is it only about myc? how to approach the diagnosis of diffuse large B-cell lymphomas
		L. Quintanilla-Martinez, Tuebingen (Germany)
Auditorium, University Campus	VIII.	Treatment of CLL, where are we heading?
		S.M. O'Brien, Irvine, CA (USA)
Aula Magna, University Campus	VI.	FDG-pet as a biomarker in lymphoma: from qualitative to quantitative analysis
		M. Meignan, Creteil (France)
09:00–10:35 Room A and Marquee (overflow area)	Abstract number	SESSION 7 - LYMPHOMA BIOLOGY AND GENOMICS II
		Co-Chairs: T.M. Mak, Toronto, ON (Canada) and L. Pasqualucci, New York, NY (USA)
09:00	111	Isocitrate dehydrogenase (IDH) mutations in angioimmunoblastic T-cell lymphoma (AITL)
		T.M. Mak Toronto, ON (Canada)
09:20	112	Recurrent mutations in TCR (pathway)-related genes in TFH-derived peripheral T-cell lymphomas
		D. Vallois, Lausanne (Switzerland)
09:35	113	HBZ, BCL-XL, AKT, and loss of INK4A/ARF synergistically transform primary murine T-cells and elicit ATL-like disease in mice
		Y. Kasugai, Nagoya (Japan)
09:50	114	Whole genome sequencing in the framework of ICGC MMML-SEQ identifies PCBP1 as recurrently mutated in burkitt lymphoma
		S.M. Aukema, Kiel (Germany)
10:05	115	Gene, mirna and pathway specific protein expression analysis in newly diagnosed MYC/BCL2 double expressing diffuse large B-cell lymphoma
		E. Matsuki, New York, NY (USA)
10:20	116	Mechanisms of malignant transformation in TP53 wild-type burkitt lymphoma identified by integration of molecular and functional genomics data
		J. Hüllein, Heidelberg (Germany)
09:00–10:30 5 parallel sessions		‘CASE DISCUSSION’ SESSIONS
Room B		Aggressive lymphoma
		Chair: A. Lopez-Guillermo, Barcelona (Spain)
		Discussants: U. Vitolo, Turin (Italy) and P. Hamlin, New York, NY (USA)
Room C		Lymphoma radiotherapy
		Chair: L. Specht, Copenhagen (Denmark)
		Discussants: U. Ricardi, Turin (Italy) and J. Yahalom, New York, NY (USA)
Cinema Corso		Multiple myeloma
		Chair: S.V. Rajkumar, Rochester, MN (USA)
		Discussants: M. Cavo, Bologna (Italy) and M. Coleman, New York, NY (USA)
Auditorium, University Campus		Mantle cell lymphoma
		Chair: S. Le Gouill, Nantes (France)
		Discussants: M. Martelli, Rome (Italy) and P. Martin, New York, NY (USA)
Aula Magna, University Campus		Clinico-pathological discussion: border-line cases*
		Chair: M. Ghielmini, Bellinzona (Switzerland)
		Presenters: S. Dirnhofer, Basel (Switzerland), E. Campo, Barcelona (Spain) and S.H. Swerdlow, Pittsburgh, PA (USA)
		Discussants – M. Federico, Modena (Italy) and C.H. Moskowitz, New York, NY (USA)
		*supported by an unrestricted grant by sigma-tau Research Switzerland SA
10:30–11:00 Marquee		COFFEE BREAK
11:00–12:05 Room A, B and Marquee (overflow area)		SESSION 8 – HODGKIN'S LYMPHOMA
		Co-Chairs: R. Küppers, Essen (Germany) and J.A. Radford, Manchester (UK)
11:00	117	Introduction: Biology of Hodgkin lymphoma
		R. Küppers, Essen (Germany)
11:20	118	Interim pet-adapted chemotherapy in advanced hodgkin lymphoma (HL). Results of the second interim analysis of the Italian GITIL/FIL DH0607 trial
		A. Gallamini, Nice (France)
11:35	119	Interim pet response-adapted therapy in advanced stage hodgkin's lymphoma: Final results of the Phase II part of the fondazione italiana LINFOMI (FIL) HD0801 study
		P.L. Zinzani, Bologna (Italy)
11:50	120	Analysis of primary-refractory hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant
		C.H. Moskowitz, New York, NY (USA)
12:05–13:00 Room E		13-ICML PRESS CONFERENCE
		(open to all journalists)
12:05–13:00 Marquee		LUNCH TIME AND POSTER VIEWING
		from 12:30 to 13:00 authors in front of their posters for discussion with attendees
13:00–13:50 Room A, B and Marquee (overflow area)		JOHN ULTMANN MEMORIAL LECTURE*
		Chair: E.S. Jaffe, Bethesda, MD (USA)
		*sponsored by European School of Oncology – ESO
	003	Thirty years of progress in cutaneous lymphoma research
		R. Willemze, Leiden (The Nederlands)
13:50–15:20 Room A, B and Marquee		SESSION 9 – INDOLENT LYMPHOMA
		Co-Chairs: B.S. Kahl, Madison, WI (USA) and A. Lopez-Guillermo, Barcelona (Spain)
13:50		13-ICML WORKSHOP REPORT
		R.D. Gascoyne, Vancouver, BC (Canada)
14:05	121	Risk of transformation of follicular lymphoma and outcome in the immunochemotherapy era: ancillary study from the prima trial
		C. Sarkozy, Pierre Bénite (France)
14:20	122	Complete response rate at 30 months (CR30) as a surrogate endpoint in first-line follicular lymphoma: a prospectively specified analysis using individual patient data
		D.J. Sargent, Rochester, MN (USA)
14:35	123	Gadolin: primary results of a Phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent lymphoma
		B.D. Cheson, Washington, D.C. (USA)
14:50	124	A simple and effective malt lymphoma-specific prognostic index generated from the dataset of the IELSG-19 controlled clinical trial
		C. Thieblemont, Paris (France)
15:05	125	BING-NEEL syndrome: a multi-institutional retrospective study
		J.J. Castillo, Boston, MA (USA)
15:20–15:40		BREAK
15:40–16:15 Room A, B and Marquee (overflow area)		CONTROVERSY
		Early-stage HL: should interim pet-based therapy be considered routine clinical practice?
		Chair: T.A. Lister, London (UK)
	006	NO: M. Hutchings, Copenhagen (Denmark) vs
	007	YES: J.M. Connors, Vancouver, British Columbia (Canada)
16:15–17:45 Room A, B and Marquee (overflow area)		SESSION 10 – AGGRESSIVE LYMPHOMA
		Co-Chairs: U. Vitolo, Turin (Italy) and L.H. Sehn, Vancouver, BC (Canada)
16:15	126	Gray zone lymphoma (GZL): characteristics, outcomes and prognostication among a large multicenter cohort
		A.M. Evens, Boston, MA (USA)
16:30	127	Ratios of T-cells to tumour associated macrophages and PD-1 axis molecules, add to the predictive power of conventional prognosticators in diffuse large B-cell lymphoma
		M. Gandhi, Brisbane (Australia)
16:45	128	Continued risk of relapse independent of treatment modality in limited stage diffuse large B-CELL Lymphoma: final and long-term analysis of SWOG study S8736
		D.M. Stephens, Salt Lake City, UT (USA)
17:00	129	Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: Does modern chemotherapy replace the need for radiotherapy?
		J.A. Vargo, Pittsburg, PA (USA)
17:15	130	Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B-cell lymphoma (IPI 3-5) yields a good outcome without transplantation: a Phase 2 UK NCRI/LLR trial
		A.K. McMillan, Nottingham (UK)
17:30	131	Validation of the german high-grade non-hodgkin lymphoma study group (DSHNHL) prognostic model for CNS relapse in a large cohort of PET/CT staged patients
		T.C. El-Galaly, Aalborg (Denmark)
17:45 Marquee		FAREWELL APERO

Saturday, June 20, 2015

08:00–10:30 Room 159, University Campus		SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING*
		A. Kiil Berthelsen, Copenhagen (Denmark), S. Qi, New York, NY (USA) and Beijing (China) and L. Specht, Copenhagen (Denmark)
		Organized by International Lymphoma Radiation Oncology Group – ILROG and European Society for Radiotherapy and Oncology – ESTRO
		* compulsory pre-registration
08:30–10:00 2 parallel sessions
Room A		SESSION 11 – PRIMARY CNS LYMPHOMA
		Co-Chairs: G. Illerhaus, Stuttgart (Germany) and A.J. Ferreri, Milan (Italy)
08:30	132	High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous body aspirates
		I. Bonzheim, Tuebingen (Germany)
08:45	133	Genetic basis of primary central nervous system lymphoma
		K. Yoshida, Kyoto (Japan)
09:00	134	Rituximab, methotrexate, procarbazine and lomustine for elderly primary CNS lymphoma patients – the primain-study by the german cooperative PCNSL group
		B. Kasenda, Stuttgart (Germany)
09:15	135	Management and outcome of primary cns lymphoma at first relapse/progression: Analysis of 256 patients from the French LOC network
		S. Langner-Lemercier, Rennes (France)
09:30	136	Phase I/II study of TEDDI-R with ibrutinib in untreated and relapsed/refractory primary CNS lymphoma
		K. Dunleavy, Bethesda, MD (USA)
09:45	137	Lenalidomide is highly active in recurrent cns lymphomas: Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide as maintenance monotherapy
		J.L. Rubenstein, San Francisco, CA (USA)
08:40–10:00 Room B		SESSION 12 – IMMUNOTHERAPY
		Co-Chairs: R. Levy, Stanford, CA (USA) and F. Morschhauser, Lille (France)
08:40	138	Introduction: Immunotherapy of lymphoma 2015
		R. Levy, Stanford, CA (USA)
09:00	139	Phase II trial of chimeric antigen receptor modified T-cells directed against CD19 in relapsed/refractory diffuse large B-cell, follicular, and mantle cell lymphomas
		S.J. Schuster, Philadelphia, PA (USA)
09:15	140	A Phase II a study of single-agent MOR208, an FC-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-hodgkin's lymphoma
		P.L. Zinzani, Bologna (Italy)
09:30	141	Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
		S. Stilgenbauer, Ulm (Germany)
09:45	142	Two doses of polatuzumab vedotin in patients with relapsed/?refractory (R/R) follicular lymphoma (FL): durable responses at lower dose
		F. Morschhauser, Lille (France)
10:00–11:20 Room A and B		SESSION 13 – TARGETTING INTRACELLULAR PATHWAYS
		Co-Chairs: M. Seto, Nagoya (Japan) and J.F. Seymour, Melbourne (Australia)
10:00	143	Introduction: Genetic and epigenetic heterogeneity of malignant lymphoma: challenging features
		M. Seto, Nagoya (Japan)
10:20	144	Epigenetic control of cellular senescence in tumor development and lymphoma treatment
		C.A. Schmitt, Berlin (Germany)
10:35	145	Phase 1 study of E7438 (EPZ-6438), an enhancer of ZESTE-HOMOLOG 2 (EZH2) inhibitor: dose determination and preliminary activity in non-hodgkin lymphoma
		V. Ribrag, Villejuif (France)
10:50	146	Selinexor shows activity in double-hit diffuse large B-cell lymphoma in pre-clinical models and in-patients with relapsed/?refractory double-hit DLBCL
		R. Garzon, Columbus, OH (USA)
11:05	147	Phase 1 preliminary safety, efficacy and biomarker data from venetoclax (ABT-199/GDC-0199) + bendamustine and rituximab in R/R non-hodgkin's lymphoma
		S. de Vos, Los Angeles, CA (USA)
11:20–11:45 Room A and B		13-ICML HIGHLIGHTS
		TAKE HOME MESSAGES
		J.W. Friedberg, Rochester, NY (USA)
11:45–11:55		CLOSURE AND FAREWELL
		F. Cavalli, Bellinzona (Switzerland)
13:30–18:00 Room B		WORKSHOP: ‘CANINE LYMPHOMAS: STATE OF THE ART AND COMPARATIVE ASPECTS WITH HUMAN DISEASE’*
		Co-Chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)
		Organized by the European Canine Lymphoma Group
		*open to all 13-ICML attendees

This icon denotes presentations that will be available online, only for 13-ICML attendees, between July 15 and September 15, 2015.

Please note that this version of the program (last updated on May 08, data of printing) may differ from the final program. Changes communicated to 13-ICML Secretariat after this date could not be included.

EDUCATIONAL BOOK

LIST OF MEET THE PROFESSOR ARTICLES:

• I.Hodgkin Lymphoma: Special Challenges and SolutionsJoseph M. Connors, Vancouver, BC (Canada)
• II.Challenges in the management of PTLDGianluca Gaidano, Novara (Italy)
• III.Current Concepts in Primary Central Nervous LymphomaGerald Illerhaus, Stuttgart (Germany)
• IV.Masses in the Mediastinum: Primary Mediastinal Lymphoma and Intermediate TypesPeter M.W. Johnson, Southampton (UK)
• V.Smoldering Multiple MyelomaMaria-Victoria Mateos, Salamanca (Spain)
• VI.FDG-PET as a Biomarker in Lymphoma: from Qualitative to Quantitative AnalysisMichel Meignan, Creteil (France)
• VII.Are lymphomas driven by epigenetic lesions?Ari M. Melnick, New York, NY (USA)
• VIII.Treatment of CLL, where are we heading?Susan M. O'Brien, Irvine, CA (USA)
• IX.Is it only about MYC? How to approach the diagnosis of Diffuse Large B-Cell LymphomasLeticia Quintanilla-Martinez, Tuebingen (Germany)
• X.Challenges and Future Directions in Peripheral T-Cell LymphomaKerry J. Savage, Vancouver, BC (Canada)
• XI.Management of pediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?Birgit Burkhardt, Muenster (Germany) and John F. Seymour, Melbourne (Australia)
• XII.Therapeutic Exploitation of Autologous T-Cell Activation in B-Cell LymphomaAnas Younes, New York, NY (USA)

LIST OF EDUCATIONAL SYMPOSIA ARTICLES:

• XIII.Molecular pathogenesis of transformed lymphomasDavide Rossi, Novara (Italy)
• XIV.The pathology of transformation of lymphomaRandy D. Gascoyne, Vancouver, BC (Canada)
• XV.Clinical aspects of transformed lymphomaJohn G. Gribben, London (UK)
• XVI.Early stage Hodgkin lymphomaJohn A. Radford, Manchester (UK)
• XVII.Treatment of advanced-stage Hodgkin lymphomaAndreas Engert, Cologne (Germany)
• XVIII.Management of nodular lymphocyte predominant Hodgkin lymphomaRanjana H. Advani, Stanford, CA (USA)

Note: The articles published in the 13-ICML Educational Book represent the presentations made at the “Meet the Professor” sessions and “Educational Symposia” during the 13th International Conference on Malignant Lymphoma (13-ICML) held in Lugano, Switzerland on June 17–20, 2015.

All manuscripts submitted have been subjected to peer review, and authors have been requested to disclose any relationships with the companies whose products or services are discussed in their manuscripts.

Prof Michele Ghielmini, as guest editor, has reported no financial relationships with companies whose products are mentioned in this supplement.

13-ICML Reviewers' List

The 13-ICML Local Organizing Committee wishes to thank the following colleagues for their professional help:

• S.M. Ansell, Rochester, MN (USA)
• J.O. Armitage, Omaha, NE (USA)
• T.T. Batchelor, Boston, MA (USA)
• P. Boffetta, New York, NY (USA)
• E. Campo, Barcelona (Spain)
• L. Ceriani, Bellinzona (Switzerland)
• B.D. Cheson, Washington, DC (USA)
• J.M. Connors, Vancouver, BC (Canada)
• F.E. Cotter, London (UK)
• R. Dalla-Favera, New York, NY (USA)
• A. Davies, Southampton (UK)
• L.M. DeAngelis, New York, NY (USA)
• M.A. Dimopoulos, Athens (Greece)
• S. Dirnhofer, Basel (Switzerland)
• R. Dolcetti, Aviano (Italy)
• M. Dreyling, Munich (Germany)
• K. Dunleavy, Bethesda, MD (USA)
• A. Engert, Cologne (Germany)
• M. Federico, Modena (Italy)
• A.J. Ferreri, Milan (Italy)
• M.F. Fey, Bern (Switzerland)
• F. Forconi, Southampton (UK)
• F. Foss, New Haven, CT (USA)
• J.W. Friedberg, Rochester, NY (USA)
• A. Gallamini, Nice (France)
• R.D. Gascoyne, Vancouver BC (Canada)
• P. Gaulard, Créteil (France)
• M.K. Gospodarowicz, Toronto Ontario (Canada)
• M. Hallek, Cologne (USA)
• O.R. Hermine, Paris (France)
• M. Hutchings, Copenhagen (Denmark)
• E.S. Jaffe, Bethesda, MD (USA)
• P.W.M. Johnson, Southampton (USA)
• R. Küppers, Essen (Germany)
• J.P. Leonard, New York, NY (USA)
• R. Levy, Stanford, CA (USA)
• T.A. Lister, London (UK)
• A. Lopez-Guillermo, Barcelona (Spain)
• S. Luminari, Modena (Italy)
• M.V. Mateos, Salamanca (Spain)
• M. Meignan, Créteil (France)
• M. Crump, Toronto, ON (Canada)
• S. Montoto, London (UK)
• G.S. Nowakowski, Rochester, MN (USA)
• S.M. O'Brien, Irvine, CA (USA)
• L. Pasqualucci, New York, NY (USA)
• M. Pillon, Padua (Italy)
• M.A. Piris, Santander (Spain)
• J. Radford, Manchester (UK)
• S.V. Rajkumar, Rochester, MN (USA)
• U. Ricardi, Turin (Italy)
• D. Rossi, Novara (Italy)
• G. Salles, Pierre Bénite (France)
• M. Seto, Nagoya (Japan)
• J.F. Seymour, Melbourne (Australia)
• M.A. Shipp, Boston, MA (USA)
• L. Specht, Copenhagen (Denmark)
• M. Spina, Aviano (Italy)
• L.M. Staudt, Bethesda, MD (USA)
• C. Thieblemont, Paris (France)
• K. Tobinai, Tokyo (Japan)
• R. Tsang, Toronto, Ontario (Canada)
• U. Vitolo, Turin (Italy)
• J.M. Vose, Omaha, NE (USA)
• M. Weller, Zurich (Switzerland)
• W. Wössmann, Giessen (Germany)
• K.H. Young, Houston, TX (USA)
• A. Younes, New York, NY (USA)
• P.L. Zinzani, Bologna (Italy)